Skip to main content
TipRanks
Go Ultimate75% OFF

Cellectar Biosciences (NV40) Q3 2026 Earnings Report

1 Followers

DE:NV40 Q3 2026 EPS Results

Actual EPS
-EUR 0.42
Consensus EPS
-EUR 0.50
Beat/Miss
Beat by +EUR 0.09
One Year Ago EPS
-EUR 1.27

DE:NV40 Q3 2026 Revenue Results

Actual Revenue
EUR 0
Expected Revenue
EUR 0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2026
Date
11/10/2026
Time
Before Open
Conference Call
Tuesday, November 10, 2026
DE:NV40 Upcoming Earnings

Cellectar Biosciences's next earnings date is estimated for March 11, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:NV40 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 10, 2026|% Change Since:0.00%|
Earnings Call Sentiment|Positive

The call was predominantly positive, with management highlighting progress toward the phase III confirmatory trial, a first-quarter 2027 first-patient target, a planned NDA submission in the first half of 2027, encouraging WM response data, an eight-year complete response in a DLBCL case study, continued platform expansion, and sufficient cash runway into the second quarter of 2027. The main negatives were higher operating expenses and net loss, a roughly nine-month deferral of the European submission, and continued uncertainty around the precise FDA enrollment requirement. Highlights significantly outweighed the lowlights.

Company Guidance

Management expects cash runway to extend into the second quarter of 2027; to dose the first patient in the confirmatory phase III trial in the first quarter of 2027 and have several sites active and initiated this year; to submit an NDA in the first half of 2027; and, if approved, for Iopofosine I-131 to become commercially available in the U.S. as early as late 2027 or early 2028. The phase I-B dosimetry study is expected to enroll 20-30 patients, with first patient in around the first quarter of the year, while the European submission is expected to be deferred by approximately nine months. For the confirmatory study, management said the FDA requires at least one patient but not fully enrolled at regulatory action, and consultants suggested targeting between 5%-15% enrollment at the time of regulatory action; site activation is being compressed from a typical 9 to 12-month process into a five to six-month process. Management also said 80% of patients reside in about 15 of U.S. states and noted that the prior phase IIb pivotal study had approximately 50 sites worldwide.

  • Confirmatory Phase III Trial Progressing Toward First Patient DosingSite activation and study startup activities for the global confirmatory phase III trial are underway, with the company remaining on track to dose the first patient in the first quarter of 2027. Management stated that the trial is being advanced for both regulatory and commercial purposes.
  • NDA Submission and Potential Commercial Availability TimelineCellectar remains on track to submit an NDA for accelerated approval in the first half of 2027. If approved, Iopofosine I-131 could become commercially available in the United States as early as late 2027 or early 2028.
  • Strong CLOVER-WaM Results Following BTK Inhibitor TherapyIn a subgroup of patients treated immediately following BTK inhibitor therapy, Iopofosine I-131 produced an overall response rate of 87.5%, a major response rate of 79.2%, a clinical benefit rate of 100%, and a median duration of response of 16 months.
  • Additional WM Data Planned for ASHCellectar announced three upcoming ASH presentations, including updated 12-month follow-up data from CLOVER-WaM, an analysis of duration of response by prior lines of therapy, and the first public presentation of the confirmatory phase III trial design.
  • Phase I-B Dosimetry Study InitiatedThe company initiated a phase I-B dosimetry study of Iopofosine I-131 in WM that is expected to enroll 20-30 patients, including newly diagnosed and relapsed patients without a specific prior-treatment requirement. The study will evaluate tissue uptake using the same dosing regimen as the phase II-B and phase III confirmatory studies and will generate additional efficacy and safety data.
  • Potential Earlier-Line WM OpportunityManagement stated that the phase I-B study may provide prospective data on patients treated earlier in the disease course. A post-hoc CLOVER-WaM analysis to be presented at ASH suggests that patients receiving Iopofosine I-131 after fewer prior lines of therapy may achieve more durable responses.
  • Long-Duration Complete Response in DLBCL Case StudyA heavily pretreated DLBCL patient with four prior lines of therapy and high-grade double-hit disease achieved a partial response by day 48 and a complete response by day 85 after a single administration of Iopofosine I-131. The patient remained in complete response more than eight years later without disease progression or additional anti-cancer therapy.
  • Broader Applicability Across Hematologic MalignanciesManagement said the data across WM, DLBCL, and other hematologic malignancies continue to support the broader applicability of Iopofosine I-131 and the underlying Phospholipid Drug Conjugate platform across multiple cancer settings.
  • PDC Platform Engagement and Pipeline ExpansionCellectar hosted an educational webinar on the biology of phospholipid ethers and its proprietary Phospholipid Drug Conjugate technology. Management reported strong participation and engagement and stated that the platform supports Iopofosine I-131, CLR 125, and additional targeted radiotherapeutic programs.
  • CLR 125 Clinical Development AdvancingEnrollment continues in the CLR 125 phase I-B program, an iodine-125 Auger-emitting radiotherapeutic candidate in triple-negative breast cancer. The company remains on track to present initial dosimetry and safety data later this year at the San Antonio Breast Cancer Symposium.
  • Encouraging Preclinical CLR 125 DataPreclinical studies of CLR 125 in triple-negative breast cancer models demonstrated tumor targeting, uptake, and anti-tumor activity, supporting continued clinical development of the program.
  • Cash Position and Financing Support Near-Term MilestonesCash and cash equivalents were approximately $24.6 million as of September 30, 2026, compared with $13.2 million as of December 31, 2025. The company also completed an oversubscribed financing of up to $140 million in May, consisting of a $35 million upfront payment and $105 million in milestone-based capital. Management said the cash runway extends into the second quarter of 2027 and is sufficient for planned near-term operations, including initiation of the phase III trial and a potential NDA submission.
  • Accelerated Site Activation ProcessManagement said the company is reducing the typical 9-to-12-month site activation process to approximately five to six months and expects to have several sites active and initiated by the end of 2026, with first-patient enrollment planned for the first quarter of 2027.
  • Strong Interest From Clinical Sites and Patient CommunityCellectar reported strong engagement from academic centers, integrated oncology delivery networks, WM centers, and the WM patient community. Management also reported unaided inbound inquiries from institutions seeking to participate in the phase III trial.
  • Potential Positioning in BTK-Inhibitor-Unsuitable PatientsManagement stated that approximately 10%-20% of WM patients are MYD88 wild-type and that another 10% or 15% have CXCR4 mutations, populations in which BTK inhibitors do not work well. The company characterized the combined group as approximately 20%-30% of patients in a frontline setting for whom an alternative to a BTK inhibitor could be considered.
  • Potential Treatment Convenience and Safety DifferentiationManagement highlighted that Iopofosine I-131 is administered as four doses over approximately three months, compared with daily BTK inhibitor treatment. The company stated that Iopofosine I-131's observed adverse events are essentially transient hematologic suppression or cytopenias, while discussing the potential for lower cytopenia rates in earlier-line, less-treated patients.
  • Strategic Trial FootprintThe company is strategically selecting sites based on patient concentration, regional access, academic leadership, and community oncology networks. Management stated that approximately 80% of patients reside in about 15 U.S. states and that the site strategy is intended to improve patient access and enrollment capability. The prior phase IIb pivotal study included approximately 50 sites worldwide.
  • Regulatory Enrollment Framework ClarifiedManagement said FDA feedback indicates that the confirmatory study must be initiated and ongoing, with at least one patient enrolled, while discussions with consultants suggest targeting enrollment of approximately 5%-15% of the study at the time of regulatory action. Management clarified that the 5%-15% figure applies at regulatory action, not at the time of NDA submission.

DE:NV40 Earnings History

DE:NV40 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 11, 20272026 (Q4)-0.44-0.59――
Nov 10, 20262026 (Q3)-0.50-0.42-1.2767.38% (+0.86)
Aug 13, 20262026 (Q2)-0.47-0.52-3.0683.19% (+2.55)
May 14, 20262026 (Q1)-1.70-1.20-3.868.33% (+2.59)
Mar 04, 20262025 (Q4)-1.110.59-1.9130.95% (+2.49)
Nov 13, 20252025 (Q3)-2.28-1.27-10.8588.25% (+9.57)
Aug 14, 20252025 (Q2)-3.36-3.06-4.8837.22% (+1.82)
May 13, 20252025 (Q1)-4.43-3.80-20.0781.08% (+16.27)
Mar 13, 20252024 (Q4)-9.56-1.90-11.1282.93% (+9.22)
Nov 18, 20242024 (Q3)-8.95-10.85-23.5853.99% (+12.73)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed